PL322706A1 - Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation - Google Patents
Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberationInfo
- Publication number
- PL322706A1 PL322706A1 PL94322706A PL32270694A PL322706A1 PL 322706 A1 PL322706 A1 PL 322706A1 PL 94322706 A PL94322706 A PL 94322706A PL 32270694 A PL32270694 A PL 32270694A PL 322706 A1 PL322706 A1 PL 322706A1
- Authority
- PL
- Poland
- Prior art keywords
- azepins
- pyrolidines
- piperidines
- liberation
- hexahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14944193A | 1993-11-09 | 1993-11-09 | |
| US16514993A | 1993-12-10 | 1993-12-10 | |
| US17344993A | 1993-12-23 | 1993-12-23 | |
| US08/323,988 US5492916A (en) | 1993-12-23 | 1994-10-17 | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US08/323,998 US5492920A (en) | 1993-12-10 | 1994-10-17 | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US08/323,994 US5494919A (en) | 1993-11-09 | 1994-10-17 | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL322706A1 true PL322706A1 (en) | 1998-02-16 |
Family
ID=27558364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL94322706A PL322706A1 (en) | 1993-11-09 | 1994-11-07 | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0739204A4 (en) |
| JP (1) | JPH10506091A (en) |
| KR (1) | KR960705808A (en) |
| CN (1) | CN1174504A (en) |
| AU (1) | AU1172995A (en) |
| BG (1) | BG100555A (en) |
| BR (1) | BR9408019A (en) |
| CA (1) | CA2175218A1 (en) |
| CZ (1) | CZ134296A3 (en) |
| FI (1) | FI961951A0 (en) |
| HU (1) | HUT74733A (en) |
| LV (1) | LV11525B (en) |
| NO (1) | NO961865L (en) |
| PL (1) | PL322706A1 (en) |
| SK (1) | SK56296A3 (en) |
| WO (1) | WO1995013069A1 (en) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5767118A (en) * | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5731317A (en) * | 1995-03-10 | 1998-03-24 | Merck & Co., Inc. | Bridged piperidines promote release of growth hormone |
| US5559128A (en) * | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
| WO1996035713A1 (en) * | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
| US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| WO1997022004A1 (en) | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Assays for growth hormone secretagogue receptors |
| US6531314B1 (en) | 1996-12-10 | 2003-03-11 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
| GB9526645D0 (en) * | 1995-12-28 | 1996-02-28 | Chiroscience Ltd | Stereoselective synthesis |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| UA59384C2 (en) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Preventing bone mass loss and recovery thereof by means of prostaglandin agonists |
| AU7445498A (en) | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
| UA64751C2 (en) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Treatment of insulin tolerance using substances increasing growth hormone secretion |
| UA53716C2 (en) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| DK1077941T3 (en) * | 1998-05-11 | 2009-12-07 | Novo Nordisk As | Compounds with growth hormone releasing properties |
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| DZ2815A1 (en) * | 1998-06-12 | 2003-12-01 | Smithkline Beecham Corp | Protease inhibitors. |
| US6682908B1 (en) | 1998-07-10 | 2004-01-27 | Merck & Co., Inc. | Mouse growth hormone secretagogue receptor |
| EP1097170A1 (en) | 1998-07-13 | 2001-05-09 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
| WO2000009538A2 (en) | 1998-08-10 | 2000-02-24 | Merck & Co., Inc. | Canine growth hormone secretagogue receptor |
| EP1159292A2 (en) | 1998-08-14 | 2001-12-05 | Administrators of The Tulane Educational Fund | Compounds having growth hormone releasing activity |
| CO5150173A1 (en) * | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
| AU759022B2 (en) | 1999-02-18 | 2003-04-03 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| JP2002523368A (en) * | 1999-02-19 | 2002-07-30 | イーライ・リリー・アンド・カンパニー | Growth hormone secretagogue |
| US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| JP2002539192A (en) * | 1999-03-15 | 2002-11-19 | アクシス・ファーマシューティカルズ・インコーポレイテッド | Novel compounds and compositions as protease inhibitors |
| US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6784200B2 (en) | 2000-10-13 | 2004-08-31 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| CA2384240A1 (en) | 1999-10-15 | 2001-04-26 | Dean A. Wacker | Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| UA73530C2 (en) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | A compound having properties to release the growth hormone |
| ATE310728T1 (en) * | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGEN |
| EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
| WO2001098268A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
| US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
| MXPA03005601A (en) | 2000-12-22 | 2004-12-02 | Axys Pharm Inc | Novel compounds and compositions as cathepsin inhibitors. |
| DE10105041A1 (en) * | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases |
| CN1324008C (en) | 2001-09-14 | 2007-07-04 | 安万特药物公司 | Novel compounds and compositions as cathepsin inhibitors |
| WO2003024401A2 (en) | 2001-09-18 | 2003-03-27 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
| DE60222286T2 (en) * | 2001-09-27 | 2008-06-19 | Laboratoires Serono S.A., Coinsins | PROCESS FOR INCREASING THE TESTOSTERONE MIRROR |
| AU2002357692A1 (en) | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| WO2003042197A1 (en) | 2001-11-14 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Oligopeptides and compositions containing them as cathepsin s inhibitors |
| US7153822B2 (en) | 2002-01-29 | 2006-12-26 | Wyeth | Compositions and methods for modulating connexin hemichannels |
| TW200409630A (en) | 2002-09-12 | 2004-06-16 | Bristol Myers Squibb Co | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6919356B2 (en) | 2002-09-26 | 2005-07-19 | Bristol Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| KR101324340B1 (en) * | 2004-06-29 | 2013-10-31 | 헬신 세라퓨틱스 (유.에스.) 인크. | Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| PT1966130E (en) | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Modified lysine-mimetic compounds |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| EP1897956A1 (en) | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
| DK2468724T3 (en) | 2006-12-21 | 2016-02-22 | Zealand Pharma As | Synthesis of pyrrolidine compounds |
| EA200901077A1 (en) | 2007-02-09 | 2010-04-30 | Транзим Фарма, Инк. | MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION |
| EP2155769B1 (en) | 2007-05-04 | 2012-06-27 | Katholieke Universiteit Leuven KU Leuven Research & Development | Tissue degeneration protection |
| JP2009256298A (en) * | 2008-03-26 | 2009-11-05 | Sumitomo Chemical Co Ltd | Optical resolution method for piperidin-3-ylcarbamate compound, and its intermediate |
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| KR20160147007A (en) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2016021191A1 (en) * | 2014-08-05 | 2016-02-11 | Raqualia Pharma Inc. | Serine derivatives as ghrelin receptor agonists |
| US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| HU231150B1 (en) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Process for the separation of optical isomers of racemic ethyl 3-alkylpiperidine-3-carboxylic acid |
| DK3618847T3 (en) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP junction modulators of intercellular communication and their use in the treatment of diabetic eye disease |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| US10640467B2 (en) * | 2018-06-01 | 2020-05-05 | Theravance Biopharma R&D Ip, Llc | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| CN114805305B (en) * | 2022-04-20 | 2024-04-26 | 成都诺和晟泰生物科技有限公司 | Compound and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411890A (en) * | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| HU180925B (en) * | 1979-06-28 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem |
| GB8332704D0 (en) * | 1983-12-07 | 1984-01-11 | Pfizer Ltd | Growth promotants for animals |
| US5036045A (en) * | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
| US4782139A (en) * | 1985-10-28 | 1988-11-01 | Eli Lilly And Company | Selective chemical removal of a protein amino-terminal residue |
| US4997825A (en) * | 1986-12-22 | 1991-03-05 | Eli Lilly And Company | Synergistic treatment method |
| US5162302A (en) * | 1988-03-18 | 1992-11-10 | University Of Delaware | Endocrine manipulation to improve body composition of poultry |
| US5084442A (en) * | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
| US5137872A (en) * | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
| IE912345A1 (en) * | 1990-08-03 | 1992-02-12 | Pharmacia Ab | Treatment of human lactation failure |
| EP0559751B1 (en) * | 1990-11-26 | 1997-03-26 | RECKER, Robert R. | Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
| US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
| JP3098082B2 (en) * | 1991-12-12 | 2000-10-10 | 三井化学株式会社 | Method for producing amino-containing compound |
| US5366965A (en) * | 1993-01-29 | 1994-11-22 | Boehringer Mannheim Gmbh | Regimen for treatment or prophylaxis of osteoporosis |
| US5284841A (en) * | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
-
1994
- 1994-11-07 CZ CZ961342A patent/CZ134296A3/en unknown
- 1994-11-07 BR BR9408019A patent/BR9408019A/en not_active Application Discontinuation
- 1994-11-07 JP JP7513932A patent/JPH10506091A/en active Pending
- 1994-11-07 KR KR1019960702427A patent/KR960705808A/en not_active Application Discontinuation
- 1994-11-07 AU AU11729/95A patent/AU1172995A/en not_active Abandoned
- 1994-11-07 EP EP95902467A patent/EP0739204A4/en not_active Withdrawn
- 1994-11-07 HU HU9601230A patent/HUT74733A/en unknown
- 1994-11-07 WO PCT/US1994/012816 patent/WO1995013069A1/en not_active Application Discontinuation
- 1994-11-07 CN CN94194738A patent/CN1174504A/en active Pending
- 1994-11-07 SK SK562-96A patent/SK56296A3/en unknown
- 1994-11-07 CA CA002175218A patent/CA2175218A1/en not_active Abandoned
- 1994-11-07 PL PL94322706A patent/PL322706A1/en unknown
-
1996
- 1996-05-02 BG BG100555A patent/BG100555A/en unknown
- 1996-05-08 NO NO961865A patent/NO961865L/en unknown
- 1996-05-08 FI FI961951A patent/FI961951A0/en unknown
- 1996-05-22 LV LVP-96-151A patent/LV11525B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI961951A (en) | 1996-05-08 |
| HUT74733A (en) | 1997-02-28 |
| NO961865L (en) | 1996-07-08 |
| HU9601230D0 (en) | 1996-07-29 |
| LV11525A (en) | 1996-10-20 |
| NO961865D0 (en) | 1996-05-08 |
| CN1174504A (en) | 1998-02-25 |
| FI961951A0 (en) | 1996-05-08 |
| EP0739204A1 (en) | 1996-10-30 |
| LV11525B (en) | 1997-02-20 |
| AU1172995A (en) | 1995-05-29 |
| BG100555A (en) | 1996-10-31 |
| CZ134296A3 (en) | 1996-12-11 |
| WO1995013069A1 (en) | 1995-05-18 |
| KR960705808A (en) | 1996-11-08 |
| EP0739204A4 (en) | 2000-03-15 |
| SK56296A3 (en) | 1997-02-05 |
| JPH10506091A (en) | 1998-06-16 |
| CA2175218A1 (en) | 1995-05-18 |
| BR9408019A (en) | 1997-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL322706A1 (en) | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation | |
| EP0618347A3 (en) | Cement placement in well. | |
| EP0734398A4 (en) | Compounds and methods | |
| PL329351A1 (en) | Piperidines and pyrolydines | |
| GB2281830B (en) | I/q-modulator and i/q-demodulator | |
| PL320089A1 (en) | Eleuterobin and its analoques | |
| GB9304000D0 (en) | Door hold | |
| GB9321673D0 (en) | Pillows | |
| GB9420539D0 (en) | Process and composition | |
| GB2279919B (en) | Parafoil | |
| GB9315298D0 (en) | Methods | |
| GB2268878B (en) | Duvet | |
| GB9308051D0 (en) | Method and composition | |
| ZA948482B (en) | 10,11Béta- 2-bridged steroids | |
| GB9315271D0 (en) | Methods | |
| PL54677Y1 (en) | Nail | |
| GB9319206D0 (en) | Pulling and lasting machine | |
| AU119476S (en) | Security envelope | |
| CA73616S (en) | Step | |
| AU119127S (en) | Envelope | |
| AU120967S (en) | Envelope | |
| GB9300979D0 (en) | Tying aid | |
| GB9317497D0 (en) | Improved envelope | |
| GB9310729D0 (en) | Method and composition | |
| GB9319148D0 (en) | Compounds and methods |